Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 12/07/2025 am IST			After hours 05:30:00 am
33.64 ^USD	-1.87%		33.31	-0.98%

11/07	Sector Update: Health Care Stocks Rise Late Afternoon	MT
10/07	Sector Update: Health Care Stocks Rise Thursday Afternoon	MT

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

Published on 13/06/2025 at 19:12, updated on 13/06/2025 at 21:14

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Sector Update: Health Care Stocks Rise Late Afternoon	11/07	MT
Sector Update: Health Care Stocks Rise Thursday Afternoon	10/07	MT
Sector Update: Health Care	10/07	MT
Top Midday Stories: MP Materials Partners With DoD on Rare Earth Magnet Supply Chain; Delta Restores Full-Year Guidance	10/07	MT
BioNTech, Pfizer Urge UK Court to Overturn Moderna Vaccine Patent Ruling	10/07	MT
Moderna Wins US FDA Clearance for Updated COVID-19 Vaccine for At-risk Children	10/07	MT
Pfizer, BioNTech Appeal London Court Ruling Over Moderna mRNA Patent Dispute	10/07	MT
Moderna: Spikevax approved for children at increased risk	10/07	CF
Moderna Receives FDA Approval for Spikevax Vaccine in Children Aged Six Months to 11 Years	10/07	MT
Moderna gets full US approval for COVID shot in at-risk children 6 months and older	10/07	RE
AI Mania Masks Trade War Risks	10/07
Moderna gets full US approval for COVID-19 vaccine in children 6 months and older	10/07	RE
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win	10/07	RE
Wall St stocks edge lower as investors look for tariff clarity	09/07	RE
Wall St is mixed as investors monitor Trump's latest tariff moves	09/07	RE
US CDC ends emergency bird flu response as infections decline	08/07	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	03/07	RE
US CDC accepts ousted vaccine panel's recommendations for RSV, meningococcal shots	02/07	RE
Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10:00 AM	01/07
Health Care Up as Budget Bill Fears Ease -- Health Care Roundup	01/07	DJ
Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Value Index	01/07	CI
Sector Update: Health Care Stocks Higher Late Afternoon	01/07	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	01/07	MT
Sector Update: Health Care	01/07	MT
Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion	30/06	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

31/07 - Q2 2025 Earnings Release (Projected)

More about the company